HPV vaccine indicated for treating anal cancers
The European Commission has approved the use of Gardasil – the quadrivalent human papillomavirus vaccine – for preventing anal precancerous lesions and anal cancers that are causally related to certain oncogenic HPV types in men and women.
It is already indicated for the prevention of HPV-related cervical cancer and premalignant genital lesions in females aged nine and over.
The vaccine, which is manufactured by Sanofi Pasteur MSD, protects against HPV types 6, 11, 16, 18.
This new indication “acknowledges the efficacy of Gardasil, targeting the high-risk HPV types 16 and 18 which cause the vast majority of anal cancers”, said Sanofi in a statement.